Determination of Regulatory Review Period for Purposes of Patent Extension; SILIQ

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for SILIQ, a human biological product, and is publishing this notice as required by law. The FDA made this determination due to patent extension applications submitted to the US Patent and Trademark Office (USPTO), Department of Commerce.